J.L. Alvarez-Ossorio, M. Alvarez-Maestro, J.M. Cozar-Olmo, M. Espinosa-Bosch, I. Florido-Pérez, F. Guerrero-Ramos, L. Martinez-Piñeiro, J. Olivares-Corral, M. Rodriguez-Quecedo, O. Rodriguez-Faba
{"title":"Recomendaciones para la prevención y el tratamiento de los efectos adversos del BCG intravesical","authors":"J.L. Alvarez-Ossorio, M. Alvarez-Maestro, J.M. Cozar-Olmo, M. Espinosa-Bosch, I. Florido-Pérez, F. Guerrero-Ramos, L. Martinez-Piñeiro, J. Olivares-Corral, M. Rodriguez-Quecedo, O. Rodriguez-Faba","doi":"10.1016/j.acuro.2026.502005","DOIUrl":null,"url":null,"abstract":"<div><div>Intravesical Calmette-Guérin bacillus (BCG) instillation is the treatment of choice after transurethral resection of intermediate- and high-risk non-muscle-invasive bladder tumors (NMIBT). However, adverse effects (AEs) of BCG are common and can compromise adherence to treatment.</div><div>Therefore, a group of experts in urology, hospital pharmacy and nursing reviewed the most recent literature and developed a series of practical recommendations for the prevention, early detection, and treatment of adverse events (AEs) associated with BCG vaccination. These include a questionnaire for AE detection, the treatment of the most common local and systemic AEs, and precautionary recommendations, ranging from BCG preparation to excreta management. Special attention has been given to a multidisciplinary and coordinated approach between urologists, hospital pharmacists and nurses to optimize treatment adherence.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502005"},"PeriodicalIF":1.7000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480626000811","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Intravesical Calmette-Guérin bacillus (BCG) instillation is the treatment of choice after transurethral resection of intermediate- and high-risk non-muscle-invasive bladder tumors (NMIBT). However, adverse effects (AEs) of BCG are common and can compromise adherence to treatment.
Therefore, a group of experts in urology, hospital pharmacy and nursing reviewed the most recent literature and developed a series of practical recommendations for the prevention, early detection, and treatment of adverse events (AEs) associated with BCG vaccination. These include a questionnaire for AE detection, the treatment of the most common local and systemic AEs, and precautionary recommendations, ranging from BCG preparation to excreta management. Special attention has been given to a multidisciplinary and coordinated approach between urologists, hospital pharmacists and nurses to optimize treatment adherence.
期刊介绍:
Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology.
Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.